Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Lung Cancer ; 155: 120-126, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33798901

RESUMO

OBJECTIVES: The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear. MATERIALS AND METHODS: Retrospective medical data from advanced or recurrent NSCLC patients who were treated with nivolumab or pembrolizumab at ten institutions in Japan between January 2016 and September 2018 were analyzed. Eligible patients were divided into two groups according to the presence of pre-existing ILD. RESULTS: A total of 461 NSCLC patients were enrolled, 412 without ILD (Non-ILD group) and 49 with ILD (ILD group). The response rate (RR) and disease control rate (DCR) of the ILD group were not inferior to those of the Non-ILD group [RR: 49.0 % (24/49) vs. 30.1 % (124/412), P < 0.01 and DCR: 69.4 % (34/49) vs. 51.2 % (211/412), P = 0.016, respectively]. Non-inferior outcomes were also observed with respect to progression-free survival (PFS) and overall survival (OS) (median PFS: 5.9 months vs. 3.5 months, P = 0.14 and median OS: 27.8 months vs. 25.2 months, P = 0.74 in the ILD and Non-ILD groups, respectively). Among immune-related adverse effects (irAEs), checkpoint inhibitor pneumonitis (CIP) was more frequently observed among NSCLC patients in the ILD group [30.6 % (15/49) vs. 9.5 % (39/412), P < 0.01]. The frequency of irAEs other than CIP and infusion reactions was not significantly different between the ILD group and the Non-ILD group. CONCLUSION: These results suggest that the clinical outcomes of ICIs are not significantly affected by pre-existing ILD despite the increased frequency of CIP. NSCLC patients with ILD are therefore probable candidates for ICIs.


Assuntos
Carcinoma Pulmonar de Células não Pequenas , Doenças Pulmonares Intersticiais , Neoplasias Pulmonares , Carcinoma Pulmonar de Células não Pequenas/complicações , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Humanos , Inibidores de Checkpoint Imunológico , Japão , Doenças Pulmonares Intersticiais/complicações , Doenças Pulmonares Intersticiais/tratamento farmacológico , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/tratamento farmacológico , Recidiva Local de Neoplasia , Estudos Retrospectivos
2.
Kyobu Geka ; 68(11): 947-9, 2015 Nov.
Artigo em Japonês | MEDLINE | ID: mdl-26469263

RESUMO

Here we describe a case of an 18-year-old boy who exhibited abnormal pulmonary parenchyma supplied by an aberrant artery from the descending aorta in the right lower lobe of the lung and a cystic tumor measuring 34×26×54 mm in the right upper mediastinum. Video-assisted thoracic surgery for resection of the 2 lesions showed that they were independent of each other. Final diagnosis of an intralobar pulmonary sequestration in the right lower lobe and a bronchogenic cyst in the upper mediastinum was made. In some reports, 2 lesions were described to be in close proximity to and connected with each other, but the present case is unique in that the 2 lesions were completely independent of each other.


Assuntos
Cisto Broncogênico/cirurgia , Sequestro Broncopulmonar/cirurgia , Adolescente , Cisto Broncogênico/irrigação sanguínea , Cisto Broncogênico/diagnóstico por imagem , Sequestro Broncopulmonar/diagnóstico por imagem , Humanos , Masculino , Cirurgia Torácica Vídeoassistida , Tomografia Computadorizada por Raios X , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...